CIK 0001880438 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 820606654
- Phone
- (650) 331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 94 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-19 | Readnour Robin Shane Director | Purchase | +75,000 | $1.04 | $78K | 489,788 |
| 2024-11-19 | Zakrzewski Joseph S Director | Purchase | +5,000 | $1.01 | $5K | 123,199 |
| 2024-11-18 | Zakrzewski Joseph S Director | Purchase | +20,000 | $1.00 | $20K | 118,199 |
| 2024-11-18 | Easom Eric Chief Executive Officer | Purchase | +50,000 | $1.00 | $50K | 1,065,766 |
| 2024-11-04 | Prior Stephen David Chief Strategy Officer | Grant or award | +10,125 | 35,342 | ||
| 2024-11-04 | Prior Stephen David Chief Strategy Officer | Grant or award · Stock Option (right to buy) | +20,250 | 20,250 | ||
| 2024-11-04 | Eizen Joshua M See Remarks | Grant or award | +31,500 | 126,335 | ||
| 2024-11-04 | Eizen Joshua M See Remarks | Grant or award · Stock Option (right to buy) | +63,000 | 63,000 | ||
| 2024-08-14 | Leonard Braden Michael 10% owner | Purchase | +1,500,000 | $1.04 | $1.6M | 5,749,432 |
| 2024-08-09 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −3,410,335 | $1.08 | $3.7M | 1,725,348 |
| 2024-08-09 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −114,759 | $1.08 | $124K | 300,853 |
Page 10 of 10 · 191 trades